This afternoon we watched Roivant Sciences rise 4.8% to a price of $10.85 per share. The mid-cap Pharmaceutical company is now trading -30.3% below its average target price of $15.56. Analysts have set target prices ranging from $11.0 to $23.0 per share for Roivant Sciences, and have given the stock an average rating of buy.
The stock has an average amount of shares sold short at 7.1%, and a short ratio of 5.83. Since 30.27% of the company's shares are owned by insiders, we can infer that there is a degree of alignment between management and shareholder interests. Finally, we also note that an average number of institutional investors are invested in the stock, with 67.9% of Roivant Sciences's shares being owned by this investor type.
Institutions Invested in Roivant Sciences
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2023-09-30 | QVT Financial LP | 14% | 112,541,536 | $1,221,075,708 |
| 2023-09-30 | Viking Global Investors, L.P. | 9% | 73,434,301 | $796,762,193 |
| 2023-09-30 | SB Investment Advisers (UK) LTD | 9% | 73,031,667 | $792,393,614 |
| 2023-09-30 | FMR, LLC | 5% | 38,910,625 | $422,180,296 |
| 2023-09-30 | Morgan Stanley | 2% | 19,311,631 | $209,531,203 |
| 2023-09-30 | Blackrock Inc. | 2% | 17,723,537 | $192,300,383 |
| 2023-09-30 | Wellington Management Group, LLP | 2% | 14,842,976 | $161,046,295 |
| 2023-09-30 | Patient Square Capital LP | 2% | 12,639,920 | $137,143,136 |
| 2023-09-30 | Baker Brothers Advisors, LLC | 1% | 11,877,171 | $128,867,309 |
| 2023-09-30 | T. Rowe Price Investment Management, Inc. | 1% | 10,649,397 | $115,545,961 |
Besides an analyst consensus of strong upside potential, other market factors point to there being positive market sentiment on Roivant Sciences.
